Newton Biocapital
VC Fund
Brussels, Belgium
Newton Biocapital is a Venture Capital Fund incorporated in Belgium, focused on financing biotech and life science projects in the "core of Europe" (B, NL, D, F) and Japan for the prevention and treatment of chronic diseases.Their approach as lead investor is to support promising start-up projects as well as neglected or undervaluedlate-stage projects, in order to mitigate the risks and to create investor value. The leadership team consi.sts of specialists with long-standing management and investor experience who coach bio-entrepreneurs through the development stages of their projects.
- Total investments:
- 22
- Last investment:
- Lead investor:
- 68%
- Fund size:
- $57M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Newton Biocapital invests in
Stages Newton Biocapital invests in
Countries Newton Biocapital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $2.9M–$3.2M
- Series A
- $6.1M–$84M
- Venture - Series Unknown
- $1.3M–$20M
Investment Focus
Industry
- Biotechnology 12 (55%)
- Medical 9 (41%)
- Pharmaceutical 7 (32%)
- Health Care 6 (27%)
- Medical Device 5 (23%)
Stage
- Series A 8 (36%)
- Venture - Series Unknown 4 (18%)
- Seed 3 (14%)
- Series B 2 (9%)
- Series D 2 (9%)
Country
- Belgium 8 (36%)
- Japan 4 (18%)
- France 3 (14%)
- Switzerland 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Els Hubloux
Partner
|
Partner | Total investments: 3 | Find email | |
Goro Takeda
Managing Partner
|
Managing Partner | Total investments: 0 | Find email | |
Alain Parthoens
Managing Partner and Founder
|
Managing Partner and Founder | Total investments: 7 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Founded by an experienced group of seasoned healthcare and biotech executives with extensive experience in research, drug development, and commercialisation, Bioxodes is developing a portfolio of high value products derived from natural sources based on research conducted by Prof. Edmond Godfroid. The research was conducted in collaboration withacademic groups from Université Catholique de Louvain, Facultés Universitaires Notre Dame de la Paix Namur, and Université de Liège as well as with the Université de Neuchâtel, Switzerland.The Company’s lead programme, Ir-CPI, is the first in a novel class of antithrombotics, and is being developed for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention. Thanks to a novel mechanism of action, Ir-CPI is potentially the world’s first injectable antithrombotic which can be used in all patient groups without causing high levels of bleeding and potentially without needing to be reversed or washed out at the end of critical procedures. | $6.4M / Series A / Dec 10, 2025 | ||
| Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors for the treatment of axonopathies such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair. | $83.9M / Series A / Mar 24, 2025 | ||
| Tensegrity Pharma is the developer of a novel drug designed to minimize bottlenecks and provide innovative value to patients. | $3.2M / Seed / Nov 13, 2024 | ||
| AdipoPharma SAS is dedicated to learning more about the role of adipocyte cells in diabetes. AdipoPharma is using the adipocyte's power to treat insulin resistance, type 2 diabetes, and other diseases. | Nov 11, 2024 | ||
| AdipoPharma SAS is dedicated to learning more about the role of adipocyte cells in diabetes. AdipoPharma is using the adipocyte's power to treat insulin resistance, type 2 diabetes, and other diseases. | $10.6M / Series A / Nov 11, 2024 | ||
| AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance. | $29.2M / Series A / Sep 18, 2023 | ||
| Santero Therapeutics seeks to provide novel medications with fresh modes of action that combat diseases with high resistance. Santero develops antimicrobials with novel modes of action to combat the rise of antibiotic-resistant microorganisms. | $8.6M / Series A / Jun 07, 2023 | ||
| AdipoPharma SAS is dedicated to learning more about the role of adipocyte cells in diabetes. AdipoPharma is using the adipocyte's power to treat insulin resistance, type 2 diabetes, and other diseases. | Series A / Jan 23, 2023 | ||
| DeuterOncology is a preclinical-stage biotech company focusing on the development of a first-in-class dual MET and RAS pathway inhibitor for targeted cancer therapies. | $6.1M / Series A / Jan 19, 2023 | ||
| NeuVasQ is developing drugs to restore blood-brain barrier function in acute neurological disorders such as stroke and epilepsy, as well as neurodegenerative diseases such as Alzheimer's. It is based on discoveries about the molecular mechanisms that keep the blood-brain barrier intact (BBB). The BBB regulates the exchange of informationbetween the vascular and central nervous systems (CNS). Increased BBB permeability, whether due to age or injury, plays a role in many neurological conditions by allowing harmful blood substances to enter the CNS. Many neurodegenerative disorders, such as Alzheimer's, as well as a variety of acute neurological conditions, such as stroke and epilepsy, are associated with BBB dysfunction. | $23.9M / Series A / Jun 24, 2021 | ||
| See all 22 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Newton Biocapital invest in?
Newton Biocapital invests primarily in Biotechnology, Medical and Pharmaceutical startups, most often at Series A and Venture - Series Unknown stage. Most of the 22 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Newton Biocapital's check size?
Newton Biocapital typically joins rounds of $2.9M–$3.2M at Seed, $6.1M–$84M at Series A and $1.3M–$20M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Newton Biocapital participates in.
How do I contact Newton Biocapital?
Public channels for Newton Biocapital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Newton Biocapital?
The team at Newton Biocapital includes Els Hubloux (Partner), Goro Takeda (Managing Partner) and Alain Parthoens (Managing Partner and Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
